Faisal Zain has dedicated his career to the high-precision world of medical device manufacturing, where the margin for error is thin and the potential for impact is immense. As an expert in tools for diagnostics and treatment, he has seen how outdated procedures leave patients at risk. Our conversation explores the urgent need to move away from sixty-year-old surgical methods for hydrocephalus, the innovative use of the body’s venous system to drain brain fluid, and how a significant influx of capital is paving the way for FDA approval. By focusing on a less invasive endovascular approach, we examine the potential to finally treat the vast majority of patients who currently suffer in silence.
The traditional surgical approach to managing excess brain fluid has been the gold standard for over half a century, yet it remains one of the most complication-prone procedures in neurosurgery. Could you walk us through why this sixty-year-old method is so taxing on the patient?
The reality of traditional shunt surgery is quite visceral, as it requires a surgeon to drill a burr hole directly into the patient’s skull. Once that opening is made, a tube is passed through the brain and connected to a long catheter that must be tunneled under the skin all the way down to the abdomen. It is a grueling, invasive process that leaves the body vulnerable, which explains why the rate of complication is among the highest in the entire field of neurosurgery. We see a staggering 30% to 40% of these patients requiring additional surgeries within just the first one or two years because of infections, drainage issues, or device failures. For the more than one million Americans living with this condition, the physical and emotional weight of knowing their lifeline might fail so soon is an immense burden to carry.
Moving away from the invasive nature of drilling and tunneling, how does the new eShunt technology utilize the body’s own anatomy to manage fluid more naturally?
Instead of opening the skull, this system enters the body through a small incision in the groin using a catheter that is guided to the base of the brain. There, a small implant creates a pathway that allows excess cerebrospinal fluid to drain into the body’s venous system, effectively mimicking the brain’s natural reabsorption process. By avoiding the trauma of open-brain surgery, we are seeing encouraging safety and efficacy results in the more than 200 patients treated to date. It is a sophisticated shift from mechanical plumbing to a biological-style integration that respects the body’s existing infrastructure. This method offers a sense of relief to those who previously faced the daunting prospect of invasive shunts and the cognitive impairment that comes with untreated hydrocephalus.
Financial backing is often a barometer for the potential impact of a medical innovation. How will the recent eighty-five million dollar investment round accelerate the mission to help the vast majority of patients who currently avoid treatment?
This recent $85 million Series C round, which brings the total capital raised to over $200 million, is a massive vote of confidence from industry leaders like Medtronic and Johnson & Johnson. This influx of capital is specifically designated to complete the pivotal clinical trial, which is the final hurdle before we can offer this to the broader public. Currently, fewer than 20% of hydrocephalus patients actually receive treatment because they are understandably terrified of the risks associated with traditional surgery. If we can prove that this less invasive alternative is consistently safe, we can finally reach those suffering from chronic headaches who have stayed on the sidelines for years. It is about more than just a device; it is about building the clinical evidence required to change the standard of care for an underserved population.
For those following the progress of this technology, what is the anticipated timeline for clinical milestones and eventual availability in the healthcare market?
We are moving toward a very clear set of milestones, with the expectation to submit the application for FDA premarket approval in 2027. This timeline is built on a foundation of twelve years of development and the expertise of physicians who recognized these surgical shortcomings early on. If all goes according to plan and we receive that approval, the goal is to begin bringing the product to the commercial market by 2028. Every year spent in trials is another year where patients risk severe neurological complications, so there is a profound sense of urgency within the team to maintain this momentum. Seeing the positive data from our first 200 patients gives us the drive to push through these final stages of regulatory scrutiny.
What is your forecast for the future of neurovascular treatments?
I believe we are on the cusp of a total shift where “open” brain procedures become the exception rather than the rule. In the next decade, the success of technologies like the eShunt will likely inspire a wave of endovascular solutions for conditions we once thought required a drill and a steady hand. We will see a world where neurosurgery feels less like a major trauma and more like a precise, outpatient-style intervention, significantly lowering the 30% failure rates we see today. This evolution will not only save lives but will restore the quality of life for millions who currently live in fear of the very treatments meant to save them.
